Search Results - "MacGrogan G"

Réduire le temps préanalytique dans le diagnostic anatomopathologique des affections mammaires, utopie ou réalité ?

Alternate Title: Reducing the pre-analysis time in the anatomicalpathological diagnosis of breast conditions, utopia or reality?

Authors: MacGrogan, G.¹ g.macgrogan@bordeaux.unicancer.fr

Source: Oncologie (Tech Science Press). Sep2012, Vol. 14 Issue 9, p520-524. 5p.

Impact of immunohistochemical markers, CK5/6 and E-cadherin on diagnostic agreement in non-invasive proliferative breast lesions.

Authors: MacGrogan, G. Arnould, L. de Mascarel, I. et al.

Source: Histopathology. May2008, Vol. 52 Issue 6, p689-697. 9p. 2 Charts, 1 Graph.

DNA topoisomerase IIalpha expression and the response toprimary chemotherapy in breast cancer.

Authors: MacGrogan, G. Rudolph, P. de Mascarel, I. et al.

Source: British Journal of Cancer. 8/18/2003, Vol. 89 Issue 4, p666-671. 6p.

Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French Multicentre GEFPICS* Study.

Authors: Vincent-Salomon, A MacGrogan, G Couturier, J et al.

Source: Histopathology. Apr2003, Vol. 42 Issue 4, p337-347. 11p.

Prognostic significance of immunohistochemically detected breast cancer node metastases in 218 patients.

Authors: de Mascarel, I. MacGrogan, G. Picot, V. et al.

Source: British Journal of Cancer. 7/1/2002, Vol. 87 Issue 1, p70-74. 5p.

Endocrine-responsive breast cancer special types: who cares?

Authors: Bonnefoi, H. MacGrogan, G.

Source: Annals of Oncology. Jun2012, Vol. 23 Issue 6, p1375-1377. 3p.

Ganglions sentinelles et carcinome canalaire in situ.

Alternate Title: Sentinel lymph nodes and ductal carcinoma in situ.

Authors: Tunon de Lara, C. Fournier, M. Macgrogan, G.

Source: Oncologie (Tech Science Press). Jun2013, Vol. 15 Issue 6, p331-335. 5p.

Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer.

Authors: Arnould, L Denoux, Y MacGrogan, G et al.

Source: British Journal of Cancer. 5/19/2003, Vol. 88 Issue 10, p1587-1591. 5p.

Differences in pathological and biological factors between DCIS, DCIS with microinvasion (DCIS-MI) and DCIS with concomitant invasive ductal carcinoma (DCIS-IDC).

Authors: MacGrogan, G. Baranzelli, M. C. Picquenot, J. M. et al.

Source: Cancer Research. Dec2012 Meeting Abstracts, Vol. 72 Issue 24a, p1065-1066. 2p.

Re: HER2 testing in the real world.

Authors: Vincent-Salomon A MacGrogan G Couturier J et al.

Source: JNCI: Journal of the National Cancer Institute. 4/16/2003, Vol. 95 Issue 8, p628-629. 2p.

Cancers du sein chez l’homme : à propos de 52 cas pris en charge à l’institut Bergonié de Bordeaux entre 1980 et 2004

Alternate Title: Male breast cancer: A review of 52 cases collected at the Institute Bergonié (Bordeaux, France) from 1980 to 2004

Authors: Tunon de Lara, C. Goudy, G. MacGrogan, G. et al.

Source: Gynecologie Obstetrique & Fertilite. Apr2008, Vol. 36 Issue 4, p386-394. 9p.

Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.

Authors: Luen, S.J. Viale, G. Nik-Zainal, S. et al.

Source: Annals of Oncology. Apr2023, Vol. 34 Issue 4, p397-409. 13p.

A refined molecular taxonomy of breast cancer.

Authors: Guedj, M Marisa, L de Reynies, A et al.

Source: Oncogene. 3/1/2012, Vol. 31 Issue 9, p1196-1206. 11p. 1 Diagram, 3 Charts, 4 Graphs.

368TiPSTART: A randomized phase II study in patients with triple negative, androgen receptor positive locally recurrent (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine (UCBG-306).

Authors: Bonnefoi, H Levy, C MacGrogan, G et al.

Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.

Positive predictive value of malignancy for additional calcifications found during evaluation of a synchronous breast cancer.

Authors: Vidaud, A. Deleau, F. Cantarel, C. et al.

Source: European Journal of Radiology. Dec2024, Vol. 181, pN.PAG-N.PAG. 1p.

1779P Deep learning tertiary lymphoid structures detection on HES/H&E slides and association to survival outcome in sarcoma.

Authors: Vanhersecke, L. Rodriguez, Y. Jacob, P. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS1058-S1058. 1p.

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).

Authors: Bonnefoi, H. Grellety, T. Tredan, O. et al.

Source: Annals of Oncology. May2016, Vol. 27 Issue 5, p812-818. 7p. 1 Diagram, 4 Charts.

Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.

Authors: Bossuyt, V. Provenzano, E. Symmans, W. F. et al.

Source: Annals of Oncology. Jul2015, Vol. 26 Issue 7, p1280-1291. 12p. 2 Diagrams, 3 Charts.

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.

Authors: Bonnefoi, H. Litière, S. Piccart, M. et al.

Source: Annals of Oncology. Jun2014, Vol. 25 Issue 6, p1128-1136. 9p.

Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.

Authors: Viale, G. Regan, M. M. Dell'Orto, P. et al.

Source: Annals of Oncology. Oct2011, Vol. 22 Issue 10, p2201-2207. 7p.